- Phosphorex, a drug delivery-focused CDMO, has appointed Jerry Williamson as Chief Executive Officer to lead the company’s next phase of growth.
- The company continues to expand its capabilities in lipid nanoparticle (LNP) formulation, process development, and cGMP manufacturing to support RNA, gene, and small molecule therapeutics.
Phosphorex, a contract development and manufacturing organization (CDMO) focused on drug delivery, has named Jerry Williamson as its new Chief Executive Officer. Williamson brings more than 35 years of leadership experience across bioscience and diagnostics, including CEO roles at Sengenics, NanoView Biosciences, KEW, Inc., and Metamark Genetics, as well as president positions at Genetix LLC, Biacore Inc., and Pyrosequencing, Inc.
Williamson’s appointment coincides with Phosphorex’s ongoing expansion in lipid nanoparticle (LNP) formulation, process development, and cGMP manufacturing. These capabilities support next-generation RNA, gene, and small molecule therapeutics, strengthening the company’s position in drug delivery innovation.
Trevor Wahlbrink, General Partner at Ampersand Capital Partners, said: “His exceptional leadership experience, particularly in scaling services platforms offering science-driven solutions, makes him ideally suited to lead Phosphorex through its next phase of innovation and expansion.”
Jerry Williamson added: “I’m excited to join Phosphorex and lead a team that’s at the forefront of enabling drug delivery innovation. The company has built an impressive foundation in lipid-based technologies, and I look forward to accelerating our growth and impact in partnership with our customers and investors.”
